Literature DB >> 15915000

Multidimensional voice evaluation in pretreatment glottic carcinoma.

Naoko Matsubara1, Toshiro Umezaki, Kazuo Adachi, Eri Tomita, Katsuya Matsuyama, Takashi Nakagawa, Torahiko Nakashima, Kouji Koike, Yasuhiro Kakazu, Shizuo Komune, Sohtaro Komiyama.   

Abstract

It is generally accepted that, in glottic carcinoma, the voice will deteriorate, even in the early stages. This paper reports the degree of hoarseness and multidimensional vocal evaluation of glottic carcinoma patients. Forty-seven male glottic carcinoma patients and a control group of 13 normal subjects were included in this study involving psychoacoustic evaluation by doctors, acoustic analysis, phonogram, maximum phonation time and stroboscopy before treatment. A normal voice or mild hoarseness by psychoacoustic evaluation was found in 35% of cases with T1 and T2 glottic carcinoma. Patients with psychoacoustically inferior vocalization had high scores on acoustic analysis, small phonogram areas, and short maximum phonation time. Stroboscopy revealed attenuation or disappearance of the mucosal wave on the tumor side in all cases, whether the acoustic analysis data were within or beyond the normal limits. We identified two conditions offering superior vocalization in glottic carcinoma patients: (1) the lesion should be unilateral, and (2) the lesion should be flat with no protrusion. We should evaluate patients with glottic carcinoma not only with vocal examination but also using stroboscopy before biopsy.

Entities:  

Mesh:

Year:  2005        PMID: 15915000     DOI: 10.1159/000084137

Source DB:  PubMed          Journal:  Folia Phoniatr Logop        ISSN: 1021-7762            Impact factor:   0.849


  1 in total

1.  T1 glottic carcinoma: do comorbidities, facility characteristics, and sociodemographics explain survival differences across treatment?

Authors:  Stephanie Misono; Schelomo Marmor; Bevan Yueh; Beth A Virnig
Journal:  Otolaryngol Head Neck Surg       Date:  2015-02-24       Impact factor: 3.497

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.